Adjuvant IFN alpha2 therapy of melanoma.
Kirkwood
J M
JM
Department of Medicine, University of Pittsburgh School of Medicine, University of Pittsburgh Cancer Institute, PA 17213-2582, USA.
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D018572:Disease-Free Survival; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D008545:Melanoma / Q000401:mortality / Q000556:secondary / Q000628:therapy*; D011379:Prognosis; D016032:Randomized Controlled Trials as Topic; D011994:Recombinant Proteins; D012878:Skin Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy*
D000970:Antineoplastic Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins